|
Objective: To study the myeloid antigen (CD13, CD33 and CD117) expression in multiple myeloma (multiple myeloma, MM). Method: MM patients selected by clinical performance, bone marrow cytology, imaging, serological and other indicators confirmed 22 cases, respectively, to extract the bone marrow and peripheral blood using flow cytometry, the gating by CD38/SSC and CD45/SSC set door, to detect myeloid myeloma cell membrane antigen (CD13, CD33, and CD117) and do the relevant checks, such as bone marrow cytology, DNA content, P170, blood count, renal function, protein electrophoresis, lactate dehydrogenase, β2-microglobulin and X-ray examination. Results: 1.CD13 positive rate and expression of newly diagnosed in MM without remission, disease progression and recurrence group was significantly higher than those in remission group (all P lt; 0.05), the IgA type group were significantly higher than the IgG type group (P lt ; 0.05), serum β 2-microglobulin and lactate dehydrogenase and prognostic factors were positively correlated (all P lt; 0.05), CD33, CD117 was positively correlated (all P lt; 0.05). Up to 45.5% 2.CD33 positive rate in the MM expression rate in the IgA type group was significantly higher than the IgG type group (P lt; 0.05), CD13, CD117 was positively correlated (P lt; 0.05), but not found MM other prognostic indicators related. Expression rate of 3.CD1 17 newly diagnosed in MM without remission, disease progression and recurrence group was significantly higher than the remission group (P lt; 0.05), but in different sub-type, staging differences are not significant sex nor found other prognostic factors related to MM, and CD13.CD33 was positively correlated (all P lt; 0.05). 4.MM patients most antigens in circulating myeloma cells (circulating myeloma cells, CMC) and bone marrow myeloma cells (marrow myeloma cells, MMC) have a significant positive correlation (P lt; 0.05), the CMC and serum β2- microglobulin was positively correlated (P lt; 0.05). 5.CD38/SSC located door Law tumor cells content rarely (0.5%) can be distinguished from other cells. Conclusion: 1.CD13 may indicate the progression of MM, MM's condition and prognosis may have reference value; 2.CD33 is expected to become a new target for the development of MM immunotherapy; 3.CD117 may indicate the progression of MM and CD13 CD33 was positively correlated; 4.MM patients with CMC significant correlation with MMC, CMC can directly reflect the progress of the disease, may be prompted to MM prognosis; 5CD38/SSC gating than CD45/SSC gating more sensitive, more specific, can improve the accuracy of diagnosis of MM, and is expected to become the ideal detection of minimal residual disease follow-up and monitoring of MM.
|